EGFR and neoplasm: There are various kinds of new or investigational chemotherapy drugs capable of inhibiting EGFR or FGFR, such as ABT-414 (depatuxizumab mafodotin, 1.25 mg/kg, intravenous infusion; AbbVie, Chicago, IL, USA), an investigational compound that targets a tumor-selective EGFR epitope [7]; ASP-5878 (2 mg, oral twice daily; Astellas Pharma Inc., Tokyo, Japan), a novel drug that inhibits all FGFRs [8]; and FPA-144 (bemarituzumab, 15 mg/kg, intravenous infusion; Five Prime Therapeutics, Inc., San Francisco, CA, USA), an enhanced monoclonal antibody against FGFR2b [9].